RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021
RXIIW
RXIIW was delisted on the 16th of November, 2018.
4 hedge funds and large institutions have $526K invested in RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 in 2018 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 3 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
42% less capital invested
Capital invested by funds: $904K → $526K (-$378K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$1.8K |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$273 |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$130 |
RXIIW Hedge Fund Activity: Q2 2018 in Review
4 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 (RXIIW) for Q2 2018, worth a combined $526K — down 42% from $904K a quarter earlier.
Fund positioning in RXIIW was balanced in Q2 2018: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 3 trimmed.
The largest seller was Anson Funds Management, cutting an estimated $1.8K.
- 4 institutional investors held RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 (RXIIW) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $526K of RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 stock for Q2 2018, down 42% quarter-over-quarter.
- 0 funds opened new RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 positions in Q2 2018 and 0 closed out.
- The largest RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 seller in Q2 2018 was Anson Funds Management, an estimated $1.8K sold.
Based on aggregated 13F filings for Q2 2018.